Protease‐activated receptor 2 promotes actomyosin dependent transforming microvesicles generation from human breast cancer. Issue 12 (5th September 2018)

• Record Type: Journal Article
• Authors: Das, Kaushik; Prasad, Ramesh; Singh, Arpana; Bhattacharya, Anindita; Roy, Abhishek; Mallik, Suman; Mukherjee, Ashis; Sen, Prosenjit
• Is Part Of: Molecular carcinogenesis. Volume 57:Issue 12(2018)
• Page Start: 1707
• Page End: 1722
• Publication Date: 2018-09-05
• Subjects: actin rearrangement -- blood borne microvesicles -- breast cancer metastasis -- cellular signaling -- tissue factor‐factor VIIa; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.22891
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract : Apart from blood coagulation, coagulation proteases are involved inextricably in cancer progression/propagation via intra/inter‐cellular signaling, mediated predominantly by protease‐activated receptors (PARs). Microvesicles (MVs), a plasma membrane shredded component, has recently been identified as an important contributor to human breast cancer metastasis. However, the role of PAR2 in promoting MVs generation from breast cancer cells remains largely unexplored. The objective of this study is to investigate whether coagulation protease‐mediated human breast cancer propagation commences via MVs and also to decipher the underlying signaling mechanism. Here, we elicited that coagulation factor‐FVIIa and Trypsin activates PAR2, which governs MVs shedding from MDAMB231 cells by altering actomyosin dynamics. Treatment of cells with PAR2 activators facilitate MVs generation by activating three independent (MAPK, P38, and Rho) signaling cascades. MAPK, signals through activating MLCK followed by MLC phosphorylation to alter myosin organization whereas, P38 reorganizes actin dynamics by the sequential activation of MK2 and HSP27. RhoA‐dependent ROCK‐II activation again contributes to remodeling myosin II activity. Further, both our in vitro and in vivo analyses showed that these MVs potentiate invasive and migratory property to the recipient cells. Breast cancer patients blood show an elevation of TF‐bearing, pro‐metastatic MVs than normal. These findings give an insight into the detailed signaling mechanism involved in the production of MVs with transforming ability from PAR2‐activated human breast cancer cells. Understanding these mechanistic details will certainly help to identify crucial targets for therapeutic interventions in MVs‐associated human breast cancer metastasis.